1.19
1.24%
-0.015
시간 외 거래:
1.17
-0.02
-1.68%
전일 마감가:
$1.205
열려 있는:
$1.2
하루 거래량:
6.65M
Relative Volume:
2.15
시가총액:
$430.18M
수익:
$1.21M
순이익/손실:
$-177.12M
주가수익비율:
-1.75
EPS:
-0.68
순현금흐름:
$-162.37M
1주 성능:
-41.38%
1개월 성능:
-29.59%
6개월 성능:
-31.61%
1년 성능:
-19.59%
렉시콘 파마슈티컬스 Stock (LXRX) Company Profile
명칭
Lexicon Pharmaceuticals Inc
전화
(281) 863-3000
주소
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
렉시콘 파마슈티컬스 Stock (LXRX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-03-07 | 개시 | Jefferies | Hold |
2022-08-12 | 개시 | Piper Sandler | Overweight |
2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
2021-01-29 | 다운그레이드 | Wedbush | Outperform → Neutral |
2020-12-08 | 업그레이드 | Citigroup | Neutral → Buy |
2020-11-18 | 업그레이드 | Gabelli & Co | Hold → Buy |
2019-12-11 | 다운그레이드 | Gabelli & Co | Buy → Hold |
2019-11-08 | 다운그레이드 | Citigroup | Buy → Neutral |
2019-09-11 | 업그레이드 | Gabelli & Co | Hold → Buy |
2019-07-29 | 다운그레이드 | Stifel | Buy → Hold |
2019-03-25 | 업그레이드 | Gabelli & Co | Sell → Hold |
2018-07-31 | 재확인 | Stifel | Buy |
2018-02-23 | 다운그레이드 | Needham | Buy → Hold |
2018-02-14 | 다운그레이드 | JP Morgan | Neutral → Underweight |
2017-03-01 | 재확인 | H.C. Wainwright | Buy |
2017-03-01 | 재확인 | Wedbush | Outperform |
2016-10-07 | 개시 | H.C. Wainwright | Buy |
2016-08-05 | 재확인 | Wedbush | Outperform |
2016-08-02 | 개시 | Citigroup | Buy |
2016-03-02 | 재확인 | Wedbush | Outperform |
2015-11-09 | 재확인 | Wedbush | Outperform |
2015-09-28 | 업그레이드 | Gabelli & Co | Sell → Hold |
2015-09-18 | 다운그레이드 | Gabelli & Co | Hold → Sell |
2015-08-10 | 다운그레이드 | JP Morgan | Overweight → Neutral |
모두보기
렉시콘 파마슈티컬스 주식(LXRX)의 최신 뉴스
The Analyst Landscape: 11 Takes On Lexicon Pharmaceuticals - Benzinga
Lexicon Pharmaceuticals' (LXRX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Lexicon Pharmaceuticals to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 12, 2024 - The Manila Times
Pharma Stock Has Significant Upside Potential, Analyst Says - Streetwise Reports
Lexicon to Present Preclinical IN VIVO Efficacy Data Demonstrating Ability of New Investigational Compound to Enhance and Maintain Semaglutide-Promoted Weight Loss - StockTitan
Lexicon Pharmaceuticals (NASDAQ:LXRX) Given “Hold” Rating at Needham & Company LLC - Defense World
FDA panel vote leaves Lexicon’s Zynquista hopes hanging by a thread - The Pharma Letter
Lexicon Pharmaceuticals Loses Over A Third Of Its Market Cap Post FDA Vote On Drug: Retail Sentiment Sours - Barchart
Lexicon stock in selloff on FDA AdCom rebuke (LXRX:NASDAQ) - Seeking Alpha
Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote - MarketWatch
Lexicon Pharmaceuticals (LXRX) PT Lowered to $5 at Leerink Partners - StreetInsider.com
FDA advisers vote against Lexicon Pharma's add-on drug for type 1 diabetes - Reuters.com
FDA advisers vote against Lexicon Pharma’s add-on drug for type 1 diabetes - PharmaLive
Lexicon’s Zynquista: Negative Adcomm Vote In Type 1 Diabetes Includes Support For Revised Indication - Citeline
Lexicon Pharmaceuticals Halted All Day as FDA Panel Reviews Zynquista - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista -- Update - MarketWatch
Lexicon Pharmaceuticals Gets Negative FDA Panel Vote for Zynquista - Morningstar
Lexicon Announces Outcome of FDA Advisory Committee for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease - The Manila Times
Needham & Company LLC Reaffirms "Hold" Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon’s Sotagliflozin Returns To US FDA Panel With Narrowed Indication - Citeline
Lexicon Pharmaceuticals (NASDAQ:LXRX) Shares Up 9.7%Here's Why - MarketBeat
Lexicon looks to go where no other oral drug has gone before - BioWorld Online
Biotech Stock Roundup: REGN's Drug Approval, LXRX, RYTM Stocks Gain on Update & More - MSN
Lexicon to cut 50% of workforce to focus on sotagliflozin - MSN
Lexicon reports renal benefits of diabetes drug in trial By Investing.com - Investing.com Australia
Institutions profited after Lexicon Pharmaceuticals, Inc.'s (NASDAQ:LXRX) market cap rose US$54m last week but private equity firms profited the most - Simply Wall St
Deep Dive Into Lexicon Pharmaceuticals Stock: Analyst Perspectives (9 Ratings) - Benzinga
Lexicon reports renal benefits of diabetes drug in trial - Investing.com India
Lexicon Pharma (LXRX): New Analysis of Phase 3 Data Demonstrating Renal Protective Benefits of Sotagliflozin to be Presented at ASN - StreetInsider.com
Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by HC Wainwright - MarketBeat
Lexicon Announces Completion of Screening in Phase 2B Progress Study of LX9211 in Diabetic Peripheral Neuropathic Pain (DPNP) - The Manila Times
Lexicon Pharmaceuticals (NASDAQ:LXRX) Trading 6.5% HigherTime to Buy? - MarketBeat
Lexicon pens licensing deal with Viatris for sotagliflozin - The Pharma Letter
Lexicon signs global sotagliflozin license with Viatris By Investing.com - Investing.com Australia
Peeling Back The Layers: Exploring Lexicon Pharmaceuticals Through Analyst Insights - Benzinga
Viatris Enters Exclusive Licensing Agreement With Lexicon - Contract Pharma
HC Wainwright Reaffirms Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Lexicon partners Viatris for global expansion of sotagliflozin - Yahoo Finance
Viatris to market Lexicon Pharma’s sotagliflozin outside US and Europe - World Pharmaceutical Frontiers
Viatris to market Lexicon's sotagliflozin outside of US, Europe (NASDAQ:VTRS) - Seeking Alpha
Lexicon Pharmaceuticals inks deal with Viatris for sotagliflozin - Investing.com
Lexicon Pharmaceuticals inks deal with Viatris for sotagliflozin By Investing.com - Investing.com UK
Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - The Manila Times
Lexicon Pharma (LXRX) Announces Exclusive Licensing Agreement With Viatris (VTRS) for Sotagliflozin in All Markets Outside of the U.S. and Europe - StreetInsider.com
Lexicon Pharmaceuticals, Inc. Announces Exclusive Licensing Agreement with Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe - Marketscreener.com
Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe - StockTitan
Financial Metrics Check: Lexicon Pharmaceuticals Inc (LXRX)’s Ratios for Trailing Twelve Months - The Dwinnex
Have you been able to find a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Lexicon Faces Uphill Battle As Inpefa Launch Disappoints, Eyes Type 1 Diabetes (LXRX) - Seeking Alpha
Lexicon signs global sotagliflozin license with Viatris - Investing.com
A Look at Lexicon Pharmaceuticals Inc (LXRX) Shares in the Recent Past Indicates Growth - SETE News
렉시콘 파마슈티컬스 (LXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):